Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Artivion, Inc. stock logo
AORT
Artivion
$42.42
-0.5%
$42.01
$21.97
$45.07
$2.00B1.67432,006 shs121,478 shs
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
$15.68
-0.5%
$14.82
$10.45
$20.94
$5.55B0.63732,263 shs263,515 shs
iRhythm Technologies stock logo
IRTC
iRhythm Technologies
$177.91
-2.4%
$173.57
$67.92
$187.57
$5.72B1.15450,820 shs207,910 shs
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
€26.13
+1.0%
€24.53
€17.12
€28.00
€7.91B0.57348,838 shs126,687 shs
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Artivion, Inc. stock logo
AORT
Artivion
+1.20%+4.69%+4.79%+39.56%+55.46%
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
+5.04%+5.85%+3.55%+9.95%-23.70%
iRhythm Technologies stock logo
IRTC
iRhythm Technologies
+0.25%+2.75%+4.13%+36.64%+190.81%
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
+4.15%+10.21%-4.27%+6.16%+40.35%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Artivion, Inc. stock logo
AORT
Artivion
$42.42
-0.5%
$42.01
$21.97
$45.07
$2.00B1.67432,006 shs121,478 shs
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
$15.68
-0.5%
$14.82
$10.45
$20.94
$5.55B0.63732,263 shs263,515 shs
iRhythm Technologies stock logo
IRTC
iRhythm Technologies
$177.91
-2.4%
$173.57
$67.92
$187.57
$5.72B1.15450,820 shs207,910 shs
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
€26.13
+1.0%
€24.53
€17.12
€28.00
€7.91B0.57348,838 shs126,687 shs
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Artivion, Inc. stock logo
AORT
Artivion
+1.20%+4.69%+4.79%+39.56%+55.46%
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
+5.04%+5.85%+3.55%+9.95%-23.70%
iRhythm Technologies stock logo
IRTC
iRhythm Technologies
+0.25%+2.75%+4.13%+36.64%+190.81%
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
+4.15%+10.21%-4.27%+6.16%+40.35%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Artivion, Inc. stock logo
AORT
Artivion
2.78
Moderate Buy$43.973.65% Upside
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
2.08
Hold$15.700.16% Upside
iRhythm Technologies stock logo
IRTC
iRhythm Technologies
2.80
Moderate Buy$184.853.90% Upside
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
2.71
Moderate BuyN/AN/A

Current Analyst Ratings Breakdown

Latest AORT, STVN, IRTC, and BLCO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/15/2025
iRhythm Technologies stock logo
IRTC
iRhythm Technologies
Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$175.00 ➝ $205.00
10/13/2025
iRhythm Technologies stock logo
IRTC
iRhythm Technologies
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$190.00 ➝ $195.00
10/10/2025
Artivion, Inc. stock logo
AORT
Artivion
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform
10/10/2025
Artivion, Inc. stock logo
AORT
Artivion
JMP Securities
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetMarket Outperform$42.00 ➝ $47.00
10/10/2025
iRhythm Technologies stock logo
IRTC
iRhythm Technologies
Robert W. Baird
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$180.00 ➝ $220.00
10/8/2025
Artivion, Inc. stock logo
AORT
Artivion
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
10/8/2025
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
10/8/2025
iRhythm Technologies stock logo
IRTC
iRhythm Technologies
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
10/8/2025
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold (C)
10/7/2025
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral
10/7/2025
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
Evercore ISI
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$16.50 ➝ $17.00
(Data available from 10/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Artivion, Inc. stock logo
AORT
Artivion
$388.54M5.15$0.84 per share50.44$6.59 per share6.44
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
$4.79B1.16$1.96 per share8.01$18.57 per share0.84
iRhythm Technologies stock logo
IRTC
iRhythm Technologies
$591.84M9.66N/AN/A$2.90 per share61.35
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
€1.15B6.91€0.81 per share32.38€5.02 per share5.20
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Artivion, Inc. stock logo
AORT
Artivion
-$13.36M-$0.42N/A84.84N/A-4.43%5.70%2.29%11/6/2025 (Estimated)
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
-$317M-$0.78N/A16.331.64-5.58%2.33%1.12%10/29/2025 (Estimated)
iRhythm Technologies stock logo
IRTC
iRhythm Technologies
-$113.29M-$2.93N/AN/AN/A-14.06%-90.03%-8.52%10/30/2025 (Estimated)
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
€127.45M€0.5448.3845.042.3011.73%10.34%6.21%N/A

Latest AORT, STVN, IRTC, and BLCO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/6/2025Q3 2025
Artivion, Inc. stock logo
AORT
Artivion
$0.14N/AN/AN/A$110.71 millionN/A
10/30/2025Q3 2025
iRhythm Technologies stock logo
IRTC
iRhythm Technologies
-$0.36N/AN/AN/A$184.75 millionN/A
10/29/2025Q3 2025
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
$0.16N/AN/AN/A$1.28 billionN/A
8/7/2025Q2 2025
Artivion, Inc. stock logo
AORT
Artivion
$0.11$0.24+$0.13$0.03$107.96 million$112.97 million
7/31/2025Q2 2025
iRhythm Technologies stock logo
IRTC
iRhythm Technologies
-$0.53-$0.32+$0.21-$0.44$173.94 million$186.69 million
7/30/2025Q2 2025
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
$0.06$0.07+$0.01-$0.18$1.25 billion$1.28 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Artivion, Inc. stock logo
AORT
Artivion
N/AN/AN/AN/AN/A
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
N/AN/AN/AN/AN/A
iRhythm Technologies stock logo
IRTC
iRhythm Technologies
N/AN/AN/AN/AN/A
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
N/AN/AN/AN/A1 Years
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Artivion, Inc. stock logo
AORT
Artivion
0.52
4.78
3.48
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
0.76
1.55
0.98
iRhythm Technologies stock logo
IRTC
iRhythm Technologies
6.25
5.02
4.88
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
0.25
1.79
1.22

Institutional Ownership

CompanyInstitutional Ownership
Artivion, Inc. stock logo
AORT
Artivion
86.37%
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
11.07%
iRhythm Technologies stock logo
IRTC
iRhythm Technologies
N/A
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
N/A

Insider Ownership

CompanyInsider Ownership
Artivion, Inc. stock logo
AORT
Artivion
8.10%
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
0.15%
iRhythm Technologies stock logo
IRTC
iRhythm Technologies
0.68%
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
0.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Artivion, Inc. stock logo
AORT
Artivion
1,60047.18 million43.36 millionOptionable
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
13,500354.09 million353.56 millionOptionable
iRhythm Technologies stock logo
IRTC
iRhythm Technologies
2,00032.13 million31.91 millionOptionable
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
5,521302.84 millionN/AOptionable

Recent News About These Companies

Stevanato Group (STVN) Gets a Buy from Citi

New MarketBeat Followers Over Time

Media Sentiment Over Time

Artivion stock logo

Artivion NYSE:AORT

$42.42 -0.19 (-0.45%)
As of 03:49 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo. It offers E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, a stent graft system for the treatment of infrarenal abdominal aortic aneurysms. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.

Bausch + Lomb stock logo

Bausch + Lomb NYSE:BLCO

$15.68 -0.08 (-0.48%)
As of 03:49 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. Its Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation is a subsidiary of Bausch Health Companies Inc.

iRhythm Technologies stock logo

iRhythm Technologies NASDAQ:IRTC

$177.91 -4.34 (-2.38%)
As of 03:49 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

iRhythm Technologies, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. The company also provides the Zio Monitor System, a prescription-only, remote electrocardiogram (ECG) monitoring system that consists of a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days and the Zio ECG Utilization Software System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period, including specific arrhythmia events detected by the ZEUS System; the Zio XT System is the previous generation of the Zio Monitor System and is a prescription-only, remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and the Zio AT system, a prescription-only, remote ECG monitoring system that similarly consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days and the ZEUS System, but which also incorporates the Zio AT wireless gateway that provides connectivity between the Zio AT patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with Verily Life Sciences LLC and Verity Ireland Limited to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.

Stevanato Group stock logo

Stevanato Group NYSE:STVN

€26.12 +0.27 (+1.02%)
As of 03:49 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machines. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.